Density-tunable conjugation of cyclic RGD ligands with polyion complex vesicles for the neovascular imaging of orthotopic glioblastomas

Alpha-methoxy-ω-amino PEG (MeO-PEG-NH₂; M_n = 2400; M_w/M_n = 1.11; NOF, Tokyo, Japan) was purified using an ion-exchange CM Sephadex C-50 column (GE Healthcare, Buckinghamshire, UK) before use. Alpha-acetal-ω-amino PEG (acetal-PEG-NH₂) was synthesized as described previously [27]. Beta-benzyl-l-aspartate N-carboxy-anhydride (BLA-NCA; NOF), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC; Tokyo Chemical Industry, Tokyo, Japan), Cyclo[RGDfk(CX-)] (cRGD peptide, X = 6-aminocaproic acid, -Acp; Peptide Institute, Osaka, Japan), sulfo-Cy3 mono-reactive dye (Lumiprobe, Orlando, Florida, USA), sulfo-Cy5 mono-reactive dye (Lumiprobe), DyLight488 NHS ester (Thermo Fischer Scientific, Waltham, Massachusetts, USA), methylamine solution (Me–NH₂; 40%; Wako Pure Chemical Industries, Osaka, Japan), sodium hydroxide (NaOH; Koso Chemical, Tokyo, Japan), hydrochloric acid (HCl; Koso Chemical), acetic acid (CH₃COOH; Nacalai Tesque, Tokyo, Japan), ferucarbotran (SPIO) solution (Resovist^®, Fujifilm RI Pharma, Tokyo, Japan), Blocking one (Nacalai Tesque), 4% paraformaldehyde (4% PFA; Wako), Hoechst 33342 (Hoechst; Dojindo Laboratories, Kumamoto, Japan), and other reagents were used without further purification. PBS-Tween solution (0.1% v/v PBS-T) was prepared from Dulbecco's phosphate-buffered saline (D-PBS; Wako) and Tween 20 solution (10% w/v, Wako).

Normal human umbilical vein endothelial cells (HUVECs; Lonza Japan, Tokyo, Japan) were maintained in EGM^™-2 BulletKit^™ medium (Lonza) in a humidified atmosphere of 5% CO₂ at 37 °C. BALB/c nu/nu mice (female, 18–20 g, 6 weeks old) were purchased from Oriental Yeast (Tokyo, Japan). Anti-mouse CD31 (platelet endothelial cell adhesion molecule; PECAM-1) eFluor^® 450Cyclo was purchased from eBioscience (San Diego, CA, USA). For MRI experiments, BALB/c nu/nu mice (male, 22–25 g, 8 weeks old) were purchased from Japan SLC (Hamamatsu, Japan). All animal experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals of the University of Tokyo and the National Institute of Radiological Sciences (NIRS).

The block aniomer PEG-b-poly(aspartic acid) [MeO-PEG-b-P(Asp)] and the homo catiomer n-butyl-poly([5–aminopentyl]-α,β-aspartamide) [Bu-P(Asp-AP)] were synthesized as reported previously [4, 6, 8]. To synthesize end-acetal functionalized PEG-b-poly(aspartic acid) [acetal-PEG-b-P(Asp)], BLA-NCA was polymerized using an acetal-PEG-NH₂ macroinitiator to yield end-acetal functionalized PEG-b-poly(β-benzyl-l-aspartate) (acetal-PEG-b-PBLA). Acetal-PEG-b-P(Asp) was then produced from acetal-PEG-b-PBLA by removing the benzyl group using 0.1 N NaOH.

Block aniomer solution (1.0 mg mL⁻¹; a mixture of MeO-PEG-b-P(Asp) and acetal-PEG-b-P(Asp) at a 75:25 molar ratio) and Bu-P(Asp-AP) (1.0 mg mL⁻¹) were prepared separately in 10 mM phosphate buffer (PB, pH 7.4). Both polymer solutions were mixed and vigorously stirred to form PICsomes using a vortex mixer (Scientific Industries, New York, USA). To obtain cross-linked PICsomes, 10 mg mL⁻¹ EDC solution (10 eq. versus the -COOH group in the block aniomers) was added to the PICsome solution, and the reaction was continued overnight. The resulting solution was purified by filtration (Vivaspin 6, molecular weight cutoff (MWCO): 300 000; Sartorius Stedim Biotech GmbH, Goettingen, Germany), and the acetal groups were then de-protected at pH 2.0 using 0.1 N HCl to yield aldehyde-functionalized cross-linked PICsomes. The solution was then neutralized by adding 0.1 N NaOH drop-wise, and the pH was maintained at 5.5. Finally, cRGD peptide (10 eq. versus the aldehyde group on the PICsomes) was added, and the reaction mixture was gradually frozen and thawed [28] to facilitate the formation of a thiazolidine ring between the N-terminal cysteine and the aldehyde group that converted from the acetal group [26] on the PICsomes' surface. The unbound cRGD was removed by filtration (Vivaspin 6, MWCO: 300 000), and the cRGD introduction rates were analyzed with ¹H nuclear magnetic resonance (NMR) spectroscopy (solvent, D₂O; 80 °C; JEOL LNM-ECS 400, JEOL, Tokyo, Japan) by comparing the relative peak integration values of the aromatic protons in the cRGD residues (7.2–7.5 ppm) with those of the internal standard (0 ppm, 1% wt sodium 3-(trimethylsilyl)-1-propanesulfonate: TMS), which are estimated to be 23.4% (20%-cRGD PICsomes). Other characteristics such as diameter, polydispersity index (PDI), and morphology of obtained PICsomes were confirmed using dynamic light scattering (DLS; Zetasize Nano-ZS instrument, Malvern Instruments, Malvern, UK) and transmission electron microscopy (TEM; JEM-1400 electron microscope, JEOL, Tokyo, Japan). The control PICsomes (Ctrl-PICsomes), and the 40 and 100% cRGD-conjugated PICsomes (40 and 100%-cRGD PICsomes) were prepared as described above, with slight alterations made to the molar ratios of the MeO-PEG-b-P(Asp) and acetal-PEG-b-P(Asp) from 75/25 to 100/0 for the Ctrl-PICsomes, 50/50 for the 40%-cRGD PICsomes, and 0/100 for the 100%-cRGD PICsomes. The cRGD introduction rates were estimated to be 40.4% for the 40%-cRGD PICsomes, and 97.5% for the 100%-cRGD PICsomes by NMR. The number of cRGD peptides on a single PICsome (N_cRGD) was determined with fluorescence correlation spectroscopy (FCS) using a Zeiss LSM 510 META equipped with the FCS setup ConfoCor 3 (Carl Zeiss, Germany). The values of N_cRGD were estimated to be ca. 6400 for the 100%-cRGD PICsomes, ca. 2600 for the 40%-cRGD PICsomes, and ca. 1500 for the 20%-cRGD PICsomes (see supporting information: table S1). For fluorescence imaging, the N-termini of the block aniomers were labeled with Cy3 (for in vitro experiments), Cy5 (for in vivo and intravital confocal laser scanning microscopy (IVCLSM) experiments), and DyLight488 (for IVCLSM) as described previously [17, 29, 30], and used for PICsome preparations. More detailed information is provided in the supporting information.

HUVECs (2.5 × 10³/well) were seeded into 96-well plates. After 24 h incubation, the media were replaced with fresh medium (100 μL) containing 10 μg (based on the content of the block aniomers) of Cy3-labeled cRGD-PICsomes or Cy3-labeled Ctrl-PICsomes. Subsequently, the cells were incubated for 1, 3, 6, and 24 h, and the media were then replaced with fresh media (100 μL) containing Hoechst (1 μg). After a 5 min incubation, the cells were washed again with fresh media, and the cellular uptake of the PICsomes was evaluated by high-throughput automated analysis of fluorescence images using an IN Cell Analyzer 1000 (GE Healthcare). Differences in the internalization rate of cRGD-conjugated and control PICsomes were assessed using two-way analysis of variance. Data analyses were performed using GraphPad Prism version 5.04 (GraphPad Software, La Jolla, CA, USA). For in vitro CLSM, HUVECs were seeded into 35 mm glass-base dishes (2.5 × 10⁴/dish) and treated in the same manner as described for the high-throughput automated analysis. Fluorescence images of live cells were captured using a Zeiss 780 LSM equipped with a 63 × 1.4 numerical aperture plan apochromat oil immersion objective (Carl Zeiss, Oberkochen, Germany). Images of each dish were captured after a 24 h incubation using excitation and emission wavelengths of 535 and 575–625 nm, respectively.

HUVECs (1.5 × 10⁵/well) were seeded into 6-well plates. After 24 h incubation, the media were replaced with 2 mL of fresh media containing 0.11 μg of echistatin (Tocris Bioscience, Bristol, UK), a potent irreversible α_Vβ₃ integrin antagonist. After 1 h, 200 μg (based on the content of the block aniomers) of PICsomes in 10 μL of D-PBS was added, and the cells were incubated for 3 h. Cells were washed three times with D-PBS, and 300 μL of trypsin was added and quickly removed. After 1 min, cells were collected by flushing with media, and centrifuged. The supernatants were then removed, and the cells were resuspended in 1 mL of D-PBS. Control samples were prepared in the same manner, but without the addition of echistatin. Cellular uptake of the PICsomes was then evaluated using flow cytometry (BD LSR II, BD Biosciences, San Jose, CA, USA).

To investigate the in vivo behavior of cRGD-PICsomes and Ctrl-PICsomes, female BALB/c nude mice aged 8 weeks (n = 4) were inoculated subcutaneously with U87MG human glioblastoma cells (1 × 10⁸ cells mL⁻¹, 50 μL/mouse) [17]. After 20 days, 1 mg/mouse Cy5-labeled PICsomes (based on the content of the block aniomers) was intravenously (i.v.) injected via the tail vein. The mice were sacrificed after 1, 3, 6, and 24 h, and blood was obtained from the inferior vena cava, heparinized, and centrifuged to obtain the plasma. Tumors and livers were then excised, homogenized, and centrifuged, and the supernatants were collected. The fluorescence intensity of these samples was analyzed using an IVIS imaging system (Xenogen Corporation, Alameda, CA, USA).

IVCLSM was performed using a Nikon A1R confocal LSM system attached to an upright ECLIPSE FN1 instrument equipped with a Plan Apo lambda 20 × 0.75 (DIC N2/20×) objective lens (Nikon, Tokyo, Japan), as described previously [17, 29, 30]. All pictures were acquired as spectral images from 10 μm confocal slices. Mixed solutions of DyLight488-labeled 40%-cRGD-PICsomes (5 mg mL⁻¹; 100 μL; arbitrary fluorescence units (AFU), 90 000) and Cy5-labeled Ctrl-PICsomes (5 mg mL⁻¹; 100 μL; AFU, 12 000) were administered using a tail vein catheter. Images of the tumor vasculature were acquired 1 and 6 h after administration. To confirm the effects of the fluorescent dye, experiments were performed using the opposite combination of fluorescence probes and carriers (Cy5-labeled 40%-cRGD-PICsomes (5 mg mL⁻¹; 100 μL; AFU, 12 000) and DyLight488-labeled Ctrl-PICsomes (5 mg mL⁻¹; 100 μL; AFU, 90 000)). To accurately analyze the distribution of the cRGD-PICsomes, animals were pre-injected with PECAM-1 (eFluor 450-labeled anti-mouse CD31; 0.2 mg mL⁻¹, 50 μL/mouse). Subsequently, Cy5-labeled 40%-cRGD-PICsomes (5 mg mL⁻¹; 200 μL/mouse; AFU, 12 000) were administered via a tail vein catheter. Cy5 was excited at 640 nm, and the fluorescence emissions were detected at 662–738 nm. Dylight488 was excited at 488 nm, and the fluorescence emissions were detected at 500–550 nm. PECAM-1 was excited at 405 nm, and the fluorescence emissions were detected at 425–475 nm. Data were processed using Nikon NIS-Elements C software (Nikon, Tokyo, Japan).

To assess the location of the PICsomes, the tumor tissue was excised and fixed in optimal cutting temperature compound (Sakura Finetec Japan, Tokyo, Japan). Next, 10 μm sections were cut and fixed in 4% PFA for 5 min at room temperature (r.t.) and washed with PBS-T for 1 min at r.t. After a single blocking treatment using Blocking one (Nacalai Tesque) for 10 min at r.t., the slides were incubated with monoclonal antibodies against CD31 (1:300 dilution; BD Biosciences) at a temperature of 25 °C for 30 min. They were then washed twice with PBS-T for 5 min at r.t., and incubated with a 1:300 dilution of Alexa Fluor 488-labeled goat anti-rat IgG (H + L) antibodies (Molecular Probes, Eugene, OR, USA) for 15 min at r.t. The nuclei were stained with a 1:300 dilution of Hoechst 33342. Samples were analyzed using CLSM.

Block aniomer solutions (1.0 mg mL⁻¹, mixture of MeO-PEG-b-P(Asp) and acetal-PEG-b-P(Asp) at 50:50 (mol:mol)) were prepared in 10 mM PB (pH 7.4). The resulting solutions were mixed with a one-tenth volume of diluted SPIO solution (10 mg mL⁻¹; 0.52 mg mL⁻¹ Fe). A 1.0 mg mL⁻¹ Bu-P(Asp-AP) solution was prepared separately in 10 mM PB (pH 7.4). Both polymer solutions were mixed and then stirred vigorously using a vortex mixer to form PICsomes. The cross-linked PICsomes were prepared as described in section 2.3, and SPIO-loaded PICsomes were isolated using preparative gel permeation chromatography (Sephacryl^™ S-1000, GE Healthcare). For preparation of SPIO-loaded cRGD-PICsomes, the acetal-groups were de-protected and the solutions were neutralized and purified as described in supporting information. The diameter and morphology of the PICsomes were confirmed by DLS and TEM, respectively. The inclusion of SPIO was confirmed by energy dispersive x-ray spectroscopy (EDS) analysis using a JEM-2100F (HC-STEM) system, (JEOL, Tokyo, Japan). In addition, the Fe concentration in the SPIO-loaded PICsomes was determined using inductively coupled plasma-mass spectroscopy (ICP-MS) on an Agilent 7700x ICP-MS instrument (Agilent Technologies, Palo Alto, CA, USA). The N-termini of the block aniomers were labeled with Cy5 for fluorescence imaging [5–7] and were then used for PICsome preparation. More detailed information is provided in the supporting information.

To assess the in vivo tumor accumulation of SPIO-loaded cRGD-PICsomes in an orthotopic glioblastoma model, U87MG cells were grafted (5.0 × 10⁷ cells mL⁻¹, 2 μL/mouse) by stereotaxic injection into the right caudate and putamen (depth, 3 mm) [17]. Tumors were grown for more than two weeks, and reached volumes >2.0 mm³. The mice were initially anesthetized using 3.0% isoflurane (Escain, Mylan, Tokyo, Japan), and were then ventilated using 1.5–2.0% isoflurane and an O₂:air mixture of 1:1. Polyethylene catheters (PE-10, BD) were placed in the tail vein to administer the drugs, and 2D multi-slice spin-echo (SE) and gradient-echo (GE) images were acquired 1 and 6 h after the i.v. administration of SPIO-loaded cRGD-PICsomes or Ctrl-PICsomes without cRGD ligands (dose = 40 μmol kg⁻¹ on a Fe concentration basis).

MR images were acquired using a 7.0 Tesla, 20 cm bore magnet (Bruker-Biospin, Ettlingen, Germany) interfaced with an Avance III system comprising a 2-channel high-sensitivity cooled radio frequency (RF) coil (CryoProbe, Bruker-Biospin). During the in vivo MRI experiments, rectal temperatures were monitored using an optical fiber thermometer (FOT-M, FISO Technology, Quebec, Canada), and were maintained at approximately 36.5 ± 0.5 °C using warm air and water circulation. Fast SE imaging for T₂-weighted MRI was acquired rapidly using a relaxation enhancement (RARE) sequence with the following parameters: repetition time (TR)/echo time (TE), 2000/40 ms; field of view, 25.6 × 16.0 mm²; matrix = 256 × 160; resolution = 100 × 100 μm; number of slices = 10; slice thickness, 1.0 mm with no slice gap; slice distance, transaxial; RARE factor, 8; and number of acquisition (NEX), 8. Multi-echo SE imaging for transverse relaxation rate (R₂) calculations were then performed using the following parameters: TR/TE, 3000/10–100 ms (10 echoes); NEX, 1; all other parameters were the same as those described above for the fast SE sequence. Multi-echo GE imaging for the T₂*-weighted MRI was performed as follows: TR/TE, 1000/4–58 ms in steps of 6 ms (10 echoes); flip angle, 30°; NEX, 3; all other parameters were the same as those described above. R₂ maps, which are the reciprocal of the transverse relaxation times (T₂) of water protons, were calculated using image-processing software (MRVision, version 1.6.8, MR vision, Winchester, Massachusetts, USA). The delta R₂ (ΔR₂) maps were calculated as ΔR₂ = the R₂ of the tumor region after the administration of SPIO-loaded PICsomes—the R₂ of the tumor region before administration.

Cross-linked PICsomes were prepared using an EDC reaction that coupled the carboxylic groups of the block aniomers with the amino groups of homo catiomers in the PICsome membranes. Subsequently, the cRGD peptide was conjugated onto the cross-linked PICsomes via the formation of a thiazolidine ring between the N-terminal cysteines of cRGD peptide and the aldehyde groups, which were converted from acetal groups through a deprotection reaction, on the α-ends of the PEG strands on the surface of the PICsomes (figure 1). Importantly, ligand molecules need to insert into the outer layer of the PICsomes to facilitate receptor reorganization. However, in some cases, block copolymers that were pre-functionalized with peptides before self-assembly produced undersigned molecular architectures by peptide aggregation [31]. Therefore, the 'surface modification' strategy used in the current study should be advantageous for minimizing the above subsidiary subject during PICsome formation. The density of cRGD ligands in the PICsomes was controlled by varying the ratio of MeO-PEG-b-P(Asp)/acetal-PEG-b-P(Asp) in the precursor acetal functionalized PICsomes (Ace-PICsomes). To facilitate the cRGD conjugation reactions, freezing and thawing was performed in the presence of an excess amount of cRGD (10 eq. per aldehyde group in the block aniomers of the PICsomes; see supporting information) [28]. Excess amount of Me–NH₂ was added to the PICsome solution to quench any residual aldehyde groups. Finally, the crude solution was purified by filtration to yield cRGD-conjugated and cross-linked PICsomes. Figure 2(A) shows a typical ¹H NMR spectrum of the resulting cRGD-conjugated PICsomes in D₂O. The molar percentage of the conjugated cRGD was estimated by comparing the relative peak integration values of the aromatic protons in the cRGD residues (7.2–7.5 ppm) with those in the internal standard (0 ppm, 1% wt TMS) (table 1). Representative characteristics of the cRGD-conjugated PICsomes, including particle size, PDI, zeta potential, and vesicular morphology, were measured using DLS and TEM. The mean PICsome diameter was 86–94 nm, with a relatively narrow dispersity (table 1). TEM analysis revealed that the cRGD-PICsomes formed thin-layer vesicular structures (figure 2(B)), and that the size of the obtained PICsomes was consistent with the DLS results (table 1). In addition, the zeta potentials indicated that cRGD conjugation may not affect the surface charge (table 1). Overall, these data suggest that the preparation of PICsomes with different cRGD densities was achieved without affecting the physical and chemical properties of the PICsomes.

Zoom In Zoom Out Reset image size

Zoom In Zoom Out Reset image size

The in vitro cellular internalization of 20, 40, and 100%-cRGD-PICsomes and Ctrl-PICsomes was evaluated in HUVECs, which overexpress the α_Vβ₃ and α_vβ₅ integrins that recognize cRGD [12–16]. Cellular uptake experiments were performed by the high-throughput automated analysis of fluorescence images using IN Cell Analyzer 1000. Data revealed that the strength of the fluorescence signals increased in proportion to cRGD density (figure 3(A)). In particular, a rapid increase in fluorescence signals was observed in experiments using 40%- (green line in figure 3(A)) and 100%-cRGD-PICsomes (purple line in figure 3(A)) during the initial 6 h incubation, which resulted in a >15-fold higher fluorescence intensity versus Ctrl-PICsomes after 24 h incubation. These results indicate that a high density of cRGD facilitates the binding and/or the internalization of PICsomes. CLSM experiments also revealed the importance of cRGD density. Consistent with the data obtained from the IN Cell Analyzer, the confocal images taken after the 24 h incubation enabled the direct visualization of the density-dependent association of cRGD-PICsomes into the HUVECs (figure 3(B)). Because integrins are transmembrane receptors, it was necessary to verify whether the cRGD-PICsomes were internalized into the cells. Therefore, we performed CLSM experiments with a fluorescence quenching method using trypan blue. As shown in figures 3(C) and (D), the existence of red fluorescence signals (cRGD-PICsomes) were confirmed inside the HUVEC cells. The fluorescence signals at 24 h incubation strengthened with increasing amounts of cRGD (figure 3(E)), which is consistent with the IN Cell Analyzer measurements at 24 h. Moreover, by staining the late-endosomes and lysosomes with Lyso Tracker Green, the co-localizations of cRGD-PICsomes and late-endosomes/lysosomes in HUVECs were observed (figures 3(C) and (D): right panels), indicating that cRGD promoted the cellular uptake of PICsomes.

Zoom In Zoom Out Reset image size

Next, we evaluated the binding capacity of cRGD-PICsomes to integrins on the surface of HUVECs by flow cytometry using cellular uptake inhibition assays in the presence of echistatin (figure 4). The 49-amino-acid peptide echistatin belongs to the disintegrin family, and competitively inhibits the binding of cRGD to α_Vβ₃ integrin, thereby affecting the internalization of cRGD-PICsomes. These competition experiments showed that the fluorescence peak of cells co-incubated with cRGD-PICsomes in the presence of excess echistatin was shifted to the left (figure 4; blue line), indicating reduced binding that most likely resulted from occupation of α_Vβ₃ integrin by excess free echistatin. These results suggest that integrins play an important role in the cellular uptake of cRGD-PICsomes, and that the 40 and 100% cRGD-PICsomes are candidates for further applications because they have the appropriate density of cRGD ligand on their surface.

Zoom In Zoom Out Reset image size

The in vitro experiments described in section 3.2 confirmed that the cRGD ligand could recognize α_Vβ₃ integrin. As such, tumors that have a highly angiogenic vasculature and overexpress integrins, such as glioblastoma, are a suitable model to evaluate the potential of targeting the neovasculature using cRGD-PICsomes. cRGD-PICsomes with varying ligand densities and Ctrl-PICsomes (1 mg/mouse, based on the block aniomer content in the PICsomes) were injected (i.v.) into mice bearing U87MG subcutaneous tumor xenografts, and the mice were sacrificed after 1, 3, 6, and 24 h. As shown in figure 5(A), Ctrl-PICsomes (blue line) were stable in the blood circulation, and approximately 20% of the initial dose was retained in the plasma 24 h after administration. In contrast, the density of the surface cRGD moieties affected the stability of the cRGD-PICsomes in the circulation. Specifically, 100%-cRGD-PICsomes (purple line) were eliminated rapidly (figure 5(A)). It is noteworthy that integrins, including cRGD binding integrins (e.g., α_Vβ₃ and α₅β₁), are important proteins for promoting cell−cell adhesions and are extant in various organs regardless of their quantities [12–15]. The liver is also equipped with α_Vβ₃ and/or α₅β₁ integrins [32–35]. Thus, there is a possibility that introducing cRGD might affect the accumulation of PICsomes in the liver. In fact, we observed variations in liver accumulation, particularly when the amount of cRGD was increased (figures 5(C) and (D)). Based on the accumulation profiles, a large quantity of 100%-cRGD PICsomes was captured by the liver within 3 h after injection. This might be a reason for the rapid clearance of the 100%-cRGD PICsomes from the bloodstream. Interestingly, the tumor accumulation of PICsomes was not correlated with their prolonged survival in the bloodstream; more 20%- (red line) and 40%-cRGD PICsomes (green line) accumulated in tumors than the Ctrl-PICsomes (figure 5(B)) did. A comparison of the 20 and 40%-cRGD-PICsomes reveals that the latter exhibited faster accumulation during the initial 6 h after injection (figure 5(B)). Moreover, temporal changes in the tumor-to-blood ratios indicate the utility of the 40%-cRGD-PICsomes until 6 h after their administration (figure S4). Overall, these data suggest that there is a critical balance between ligand density and biodistribution properties in terms of tumor accumulation, and 40%-cRGD PICsomes may thus have the best potential for in vivo imaging applications due to their fast and effective accumulation profile. To date, many nanocarriers have been employed in cRGD-mediated targeting to obtain better cancer diagnostic and therapeutic outcomes, because cRGD conjugation imparts the advantage of a specific binding property with nanocarriers. However, our results reveal the nonlinearity between cRGD payload and selectivity and that large liver accumulation should be the core issue in cRGD-mediated DDS. Our findings, relating to the control of cRGD density (i.e., below 40% in PICsomes) might offer the key to being able to circumvent these issues.

Zoom In Zoom Out Reset image size

The direct observation of PICsomes in vivo can provide information on their biological behavior. Therefore, we used IVCLSM for the real-time analysis of fluorescence-labeled PICsomes in living animals [17, 29, 30]. Ctrl-PICsomes and 40%-cRGD-PICsomes were labeled with Cy5 (red) and DyLight488 (green) fluorescent probes, respectively (see supporting information), and co-injected into U87MG tumor-bearing mice. Figure 6 shows IVCLSM snapshots of the tumor vasculature. One hour after administration, the blood appeared yellow (figure 6(A)), demonstrating that the Ctrl-PICsomes (red) and 40%-cRGD-PICsomes (green) were both circulating stably without aggregation. Interestingly, the 40%-cRGD-PICsomes (green) accumulated in the tumor 6 h after administration and localized around the vessel walls (figure 6(B), green), whereas Ctrl-PICsomes (red) did not selectively accumulate and remained in the circulation (figure 6(B), red). To confirm that these observations were due to specific effects of the cRGD ligand and not artifacts related to the fluorescent dye, the experiment was repeated using the opposite combination of fluorescent probes, which similarly revealed the uptake of cRGD-PICsomes, but not Ctrl-PICsomes (figure S5).

Zoom In Zoom Out Reset image size

In addition, the neovasculature was pre-stained using anti-CD31 (PECAM-1) antibodies (eFluor 450 Cyclo), which stain the endothelial layers, prior to the administration of Cy5-labeled 40%-cRGD-PICsomes (figure 7). The localization of the 40%-cRGD-PICsomes (red) was then monitored using IVCLSM. The results obtained 6 h after injection clearly revealed co-localized fluorescence signals (magenta) of 40%-cRGD-PICsomes (red) and CD-31 (blue) along the neovasculature (square regions with white dotted lines in figure 7(A)). Even 24 h after injection, the fluorescence signals of 40%-cRGD-PICsomes (red) remained in the neovasculature of the tumors (figure 7(B)). To confirm this observation, immunofluorescence staining of the same tumor was performed. Figure 7(C) confirms the co-localization of 40%-cRGD-PICsomes (red) and PECAM-1 in the tumor vasculature (green), revealing successful neovascular targeting of the cRGD-PICsomes.

Zoom In Zoom Out Reset image size

Previous studies have also demonstrated IVCLSM of neovasculature by using various cRGD-linked nanocarriers. For example, Schiffelers et al showed the rapid adhesion (∼2 min) of cRGD-linked and PEGylated-liposomes to the vessel wall in Lewis lung carcinoma [19]. Hak et al observed that cRGD-linked nanoparticles can accumulate to the tumor vasculatures within 10 min after administration [20]. These nanocarriers had similar diameters (ca. 100 nm) as the PICsomes in this study, and reported the importance of cRGD binding to its receptors by comparing the presence and absence of cRGD-ligands, but not cRGD-densities. Furthermore, other research has revealed that large cRGD-linked nanocarriers (ca. 120–320 nm) tend to restrict extravasation through tumor vasculature [18, 21] and small one (ca. 30 nm) penetrate deeper into the tumor parenchyma via transcytosis [17]. In this view, the relationship between ligand density and nanocarrier size should be the crucial factor in restricting the extravasation and/or the cRGD-mediated translocation of nanocarriers across the endothelium of the tumor vasculature. Considering that the diameter of the integrin head is 12 nm [36], it is possible that a single cRGD-linked nanocarrier with less than 12 nm cRGD-cRGD distance and an appropriate size larger than two integrin heads (e.g., more than 24 nm), can simultaneously bind to several integrin molecules when they are overexpressed and closely surrounded (figure S6(A)). To fulfill these conditions, the relationship between ligand density and the size of the nanocarriers must agree to the following equation:

$$\begin{eqnarray*}&&{{N}_{{\rm Ligand}}}=(4\times \pi \times {{r}^{2}})/(12 \times 12),\end{eqnarray*}$$

where N_Ligand is the required number of cRGDs, and r is the radius of the nanocarriers. Figure S6(B) shows the calculated relationship. For example, according to this calculation, the 100 nm nanocarriers required over 218 cRGD molecules on their surface. Although some previous reports did not mention the number of cRGD ligands on their carriers surfaces, the nanocarriers reported by Schiffelers et al [19], Mulder et al [21], and Cai et al [25], could fulfill the requirements of the above equation. FCS measurements revealed that the numbers of cRGD on cRGD-PICsomes were 6400 for the 100%-cRGD PICsomes, 2600 for the 40%-cRGD PICsomes, and 1500 for the 20%-cRGD PICsomes (table S1). In addition, we calculated the distance between two cRGD molecules on the surface of a single PICsome, and the average distances were estimated to be 2.2 nm for 100%-cRGD PICsomes, 3.5 nm for 40%-cRGD PICsomes, and 4.6 nm for 20%-cRGD PICsomes (table S1). These results indicate that the numbers of cRGDs on the surface of each PICsome was sufficient and the cRGD−cRGD distances were smaller than the size of the integrin head for multivalent binding to occur between single cRGD-linked PICsome and multiple integrin molecules. Taking into account these multivalent bindings, it can be presumed that tuning the cRGD density and carrier size enable to improve the accumulation in targeted sites such as the neovasculature. However, it is known that the multivalent bindings lead to lowered dissociation constants [37], and this might affect the restriction of extravasation and/or the translocation of the nanocarriers. Moreover, as we described in section 3.3, controlling cRGD-density enables to reduce the accumulation of nanocarriers in normal tissues, and enhance tumor accumulation. Thus, designing and tuning of cRGD-linked nanocarriers with appropriate cRGD-density and size is fundamentally important. Although further detailed studies are required to explain the whole phenomenon, our findings indicate that cRGD-linked PICsomes with 40% cRGD-density are likely a contributing factor to their localization in the endothelial layer without penetration into the tumor parenchyma and that these characteristics can be advantageous in drug delivery applications such as neovascular imaging.

PICsomes can incorporate substances into their inner hollow spaces for delivery to angiogenic sites navigated by the cRGD ligand on the PICsome surface. To use these characteristics for medical applications such as tumor diagnosis, we prepared cRGD-PICsomes that incorporated SPIO nanoparticles (ferucarbotran) approved by the US Food and Drug Administration [7] (figure 8(A)). SPIO is a widely used reagent for negative contrast MRI; therefore, SPIO-loaded cRGD-PICsomes could provide clear MR images and related information for tumor diagnosis because of their characteristic features such as their ability to survive for long periods in the circulation and their targeting ability.

Zoom In Zoom Out Reset image size

The structure of the SPIO-loaded cRGD- and Ctrl-PICsomes was confirmed using TEM. As shown in figure 8(B), SPIO incorporation did not affect the morphology of PICsomes stained with uranyl acetate. We then performed TEM without uranyl acetate staining, and incorporated SPIO were observed in the inner hollow spaces of the PICsomes (black spots in figure 8(C)). Moreover, EDS revealed the presence of Fe signals (figures S7 and S8), indicating the successful incorporation of SPIO into PICsomes. Other characteristics, such as size, zeta-potential, and Fe concentration, are listed in table S2. We also measured R₂, which is the reciprocal of the transverse relaxation time (T₂) of water protons (¹H), using in vitro MRI. Similar concentration-dependent increases in R₂ values and R₂ color mapping were observed for SPIO-loaded cRGD-PICsomes, Ctrl-PICsomes and ferucarbotran (Resovist), suggesting that they have comparable potential as contrast agents (figure S9).

Orthotopic U87MG glioblastoma was selected as a model tumor for MR imaging by SPIO-loaded cRGD-PICsomes. Both SPIO-loaded 40%-cRGD-PICsomes and Ctrl-PICsomes were administered at a dose of 40 μmol Fe kg⁻¹ for MRI measurements. Changes in the normalized R₂ values in tumor lesions over time are shown figure 9. A significant increase in normalized R₂ values was observed in SPIO-loaded cRGD-PICsomes compared with Ctrl-PICsomes. Furthermore, the unique features of SPIO-loaded cRGD-PICsomes are demonstrated in the T₂*-weighted GE images shown in figure 10(A). Specifically, glioblastoma lesions treated with cRGD-PICsomes underwent a strong reduction in signal at 1 h, which was maintained even after 6 h (figure 10(A), orange arrow). Interestingly, the ΔR₂ maps clearly show intensified signal in the tumors of mice that were administered cRGD-PICsomes (figure 10(B)). In particular, there was a significant increase in the ΔR₂ value at the rim of the glioblastoma (figure 10(B), red arrows). Because angiogenesis is correlated with tumor malignancy and is active at the tumor periphery [38], these contrast images suggest the selective binding of SPIO-loaded cRGD-PICsomes to the overexpressed α_Vβ₃ and α_vβ₅ integrins in the tumor neovasculature [16, 23, 24, 38], which is consistent with the IVCLSM images shown in figure 6. In contrast, MR images obtained from SPIO-loaded Ctrl-PICsomes were less clear (figure 10(C)), and the ΔR₂ value was also lower than that of cRGD-PICsomes (figure 10(D)). These data highlight the potential application of PICsomes in the medical field and suggest that cRGD installation might be beneficial for targeting the neovasculature, allowing enhanced MR images even in an orthotopic glioblastoma model.

Zoom In Zoom Out Reset image size

Zoom In Zoom Out Reset image size